Analystreport

Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Outlook Therapeutics, Inc.  (OTLK) 
Last outlook therapeutics, inc. earnings: 2/14 08:00 am Check Earnings Report